MapLight Therapeutics Announces $150M Private Placement; Q2 Cash $351.3M

What Happened

• On August 13, 2026, MapLight Therapeutics announced a private placement expected to raise approximately $150.0 million in gross proceeds by selling 9,197,887 shares of common stock and, for certain investors, pre-funded warrants exercisable into 3,983,168 shares. The purchase price is $11.38 per share (pre-funded warrants priced at $11.38 minus $0.0001 per underlying share). The company also filed press releases reporting Q2 financial results and disclosed cash, cash equivalents and investments of $351.3 million as of June 30, 2026.

Key Details

• Private placement size: ~9,197,887 shares of common stock and pre-funded warrants for 3,983,168 shares; expected gross proceeds ~ $150.0 million (before fees/expenses).
• Price and warrant terms: $11.38 per share; pre-funded warrants priced at $11.38 − $0.0001, exercise price $0.0001, no expiration, subject to beneficial ownership limitations (holders <20% can elect up to 19.99% with 61 days’ notice).
• Registration rights: Company must file registration statement(s) within 30 days after closing and cause effectiveness by a specified deadline; late filings can trigger liquidated damages of 1.0% of the purchaser’s amount per 30-day period (subject to caps and exceptions).
• Placement agents: Morgan Stanley, Jefferies, Leerink Partners and Stifel; MapLight will pay customary placement fees and certain expenses.

Why It Matters

• The financing materially increases MapLight’s cash runway and liquidity (cash, equivalents and investments of $351.3M as of June 30, 2026 plus ~ $150M expected proceeds), which can support development programs and operations without immediate additional equity raises. The registration rights and potential liquidated damages create a timetable and financial incentive for timely SEC registration of the securities, and the pre-funded warrants allow certain investors to take immediate ownership while limiting dilution until exercised. Investors should note the terms (price, beneficial ownership limits, and indemnities) and that the deal is subject to customary closing conditions and fees.